ArticleBiomaterials translational2026
Messenger RNA therapy in bone and joint diseases: Rationale, delivery systems, and applications.
Article in Biomaterials translational, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone and joint diseases, including bone fractures, osteoarthritis, and bone tumors, pose significant health challenges due to their debilitating effects on the musculoskeletal system. Conservative therapy and surgical treatment do not always achieve satisfactory outcomes in orthopedics, especially for degenerative bone and joint diseases. Messenger RNA (mRNA) therapy refers to the production of functional proteins and peptides by introducing mRNA into the body. The success of mRNA vaccines during the COVID-19 pandemic highlights the unique advantages of mRNA therapy, including biocompatibility, avoidance of genomic integration, and flexible, sustained delivery. These features make mRNA therapy a versatile therapeutic modality for the treatment of orthopedic diseases. In this review, we first provide an overview of the latest advances in mRNA therapy. We introduce structural modifications of mRNA and advanced gene-editing technologies, including modifications to nucleosides, mRNA domains, and codon sequences. We then discuss the development of mRNA delivery systems, such as nanomaterials, biomimetic carriers, and hydrogels, which enhance mRNA stability, reduce immunogenicity, and improve targeted delivery. This review also explores the application of mRNA therapy in orthopedic diseases, with a particular focus on its utilization in treating bone tumors and degenerative disorders. Despite promising developments, several challenges remain, including optimizing delivery efficiency, prolonging protein expression, and addressing tissue-specific barriers. Accordingly, the current limitations and future directions of mRNA therapy in orthopedic applications are emphasized. In conclusion, mRNA therapy holds great promise and may open new avenues for the treatment of orthopedic diseases and related fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.